Home › Hypopharyngeal Cancer › Pennsylvania › Philadelphia
Hypopharyngeal Cancer clinical trials in Philadelphia, PA
3 studies for Hypopharyngeal Cancer are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Thomas Jefferson University Hospital, Philadelphia
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi away
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi away
Hypopharyngeal Cancer trials in other cities
- Atlanta, GA6 studies
- Chicago, IL6 studies
- Kansas City, MO5 studies
- Richmond, VA5 studies
- Milwaukee, WI5 studies
- Peoria, IL5 studies
- Bloomington, IL5 studies
- Joliet, IL5 studies
- Wausau, WI5 studies
- Cape Girardeau, MO5 studies
- Stevens Point, WI5 studies
- Overland Park, KS4 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.